CLEC7A and Familial prostate cancer: While clec7a over-expression conferred a prior drug resistance in leukemic cells 40, 41 and was prognostic of poor prostate cancer relapse-free survival 42, it constituted as one member of the immune-related prognostic panel associated with favorable melanoma survival 43 whose mutation has been associated with immunodeficiency and the pathogenesis of retinoblastoma 44.